In recent sessions, GILD stock forecast metrics benefit from favorable HIV royalties and Hepatitis C segment stability. Earnings guidance aligns with a mid-single-digit revenue growth forecast through year-end. Using their trading system, Zack's experts give you their prediction for GILD in free RPT. Should you pass or buy Gilead ? Zacks experts tell all in a new free Special Report. Gilead Sciences, Inc. (NASDAQ:GILD), a U.S. biopharmaceutical company headquartered in Foster City, California, focuses on developing antiviral treatments for illnesses such as COVID-19, hepatitis B and C, influenza, and HIV/AIDS. GILD stock forecast for Q3 2024 shows modest upside potential, with consensus analyst target around $82.
